Multiple Ascending Dose (MDX1105-01) (Anti-PDL1)

Clinical Trial ID NCT00729664

PubWeight™ 84.16‹?›

🔗 Visit the page for NCT00729664

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 35.24
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012 2.46
4 The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015 2.17
5 Immunotherapy of cancer in 2012. CA Cancer J Clin 2012 2.12
6 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
7 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
8 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
9 Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013 1.59
10 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
11 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
12 B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013 1.53
13 Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015 1.23
14 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
15 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
16 Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer 2014 1.14
17 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
18 Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 2012 1.03
19 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
20 The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res 2012 1.01
21 T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med 2011 1.01
22 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
23 Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012 0.97
24 A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int J Mol Sci 2016 0.97
25 Current and emerging treatment options for uveal melanoma. Clin Ophthalmol 2013 0.94
26 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol 2015 0.92
27 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
28 Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw 2011 0.91
29 Overview of current immunotherapeutic strategies for glioma. Immunotherapy 2015 0.89
30 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
31 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
32 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
33 PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014 0.85
34 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
35 Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015 0.83
36 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
37 Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther 2014 0.81
38 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
39 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
40 The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016 0.81
41 New advances in targeted gastric cancer treatment. World J Gastroenterol 2016 0.81
42 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
43 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
44 Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therap Adv Gastroenterol 2016 0.78
45 Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy 2015 0.77
46 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
47 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
48 The role of checkpoints in the treatment of GBM. J Neurooncol 2015 0.75
Next 100